Synopsis
Synopsis
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Q418006
| Molecular Weight | 331.9 g/mol |
|---|---|
| Molecular Formula | C21H30ClN |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 6 |
| Exact Mass | 331.2066777 g/mol |
| Monoisotopic Mass | 331.2066777 g/mol |
| Topological Polar Surface Area | 0 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 300 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
GDUFA
DMF Review : Complete
Rev. Date : 2014-06-06
Pay. Date : 2013-09-27
DMF Number : 23171
Submission : 2009-10-05
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37062
Submission : 2022-04-25
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27607
Submission : 2013-08-02
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-04-02
Pay. Date : 2014-01-22
DMF Number : 7324
Submission : 1988-02-05
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6506
Submission : 1986-07-11
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 61
Submission : 1963-09-16
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5759
Submission : 1985-02-18
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-04-23
Pay. Date : 2012-12-03
DMF Number : 5673
Submission : 1984-12-10
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21726
Submission : 2008-03-17
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Questran Loc
Dosage Form : Oral Suspension Powder
Dosage Strength : 4g
Packaging :
Approval Date : 06-04-2021
Application Number : 2.02E+13
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Questran Loc
Dosage Form : Oral Suspension Powder
Dosage Strength : 4g
Packaging :
Approval Date : 28-01-2015
Application Number : 2.01E+13
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : Questran
Dosage Form : Cholestyramine 4G 12 Combined Oral Use
Dosage Strength : os groun 12 bust 4 g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Not Marketed
Registration Country : Norway
Brand Name : Questran
Dosage Form : Powder For Oral Suspension
Dosage Strength : 4g
Packaging :
Approval Date :
Application Number :
Regulatory Info : Not Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Questran Loc
Dosage Form : Powder For Oral Suspension
Dosage Strength : 4g
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Questran
Dosage Form : Oral Suspension Powder
Dosage Strength : 4g
Packaging :
Approval Date : 17-11-1972
Application Number : 1.97E+13
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Quantalan
Dosage Form : Oral Suspension Powder
Dosage Strength : 4g
Packaging :
Approval Date : 29-11-2006
Application Number : 2.01E+13
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Questran Loc
Dosage Form : Oral Suspension Powder
Dosage Strength : 4g
Packaging :
Approval Date : 17-11-2010
Application Number : 2.01E+13
Regulatory Info : Deregistered
Registration Country : Sweden

Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Efensol
Dosage Form : Powder For Oral Suspension
Dosage Strength : 3G
Packaging :
Approval Date : 01-09-1986
Application Number : 56701
Regulatory Info : Authorized
Registration Country : Spain

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Questran Loc
Dosage Form : Oral Suspension Powder
Dosage Strength : 4g
Packaging :
Approval Date : 15-06-2007
Application Number : 2.01E+13
Regulatory Info : Deregistered
Registration Country : Sweden

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
67
PharmaCompass offers a list of Cholestyramine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Cholestyramine manufacturer or Cholestyramine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cholestyramine manufacturer or Cholestyramine supplier.
A [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride, including repackagers and relabelers. The FDA regulates [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride supplier is an individual or a company that provides [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride active pharmaceutical ingredient (API) or [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride finished formulations upon request. The [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride suppliers may include [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride API manufacturers, exporters, distributors and traders.
click here to find a list of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride DMF (Drug Master File) is a document detailing the whole manufacturing process of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride active pharmaceutical ingredient (API) in detail. Different forms of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride DMFs exist exist since differing nations have different regulations, such as [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride DMF submitted to regulatory agencies in the US is known as a USDMF. [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride USDMF includes data on [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Drug Master File in Japan ([4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride JDMF) empowers [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride JDMF during the approval evaluation for pharmaceutical products. At the time of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride suppliers with JDMF on PharmaCompass.
A [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride CEP of the European Pharmacopoeia monograph is often referred to as a [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Certificate of Suitability (COS). The purpose of a [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride to their clients by showing that a [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride CEP has been issued for it. The manufacturer submits a [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride CEP holder for the record. Additionally, the data presented in the [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride DMF.
A [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride suppliers with CEP (COS) on PharmaCompass.
A [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride written confirmation ([4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride WC) is an official document issued by a regulatory agency to a [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride manufacturer, verifying that the manufacturing facility of a [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride APIs or [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride finished pharmaceutical products to another nation, regulatory agencies frequently require a [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride WC (written confirmation) as part of the regulatory process.
click here to find a list of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride suppliers with NDC on PharmaCompass.
[4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride GMP manufacturer or [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride GMP API supplier for your needs.
A [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride CoA (Certificate of Analysis) is a formal document that attests to [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride's compliance with [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride specifications and serves as a tool for batch-level quality control.
[4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride CoA mostly includes findings from lab analyses of a specific batch. For each [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
[4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride may be tested according to a variety of international standards, such as European Pharmacopoeia ([4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride EP), [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia ([4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride USP).